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Background Cross-sectional studies have suggested that elevated cortisol is asso-
ciated with worse physical performance, a surrogate of ageing. We
examined the relationship between repeat cortisol measures over 20
years and physical performance in later life.
Methods Middle-aged men (45–59 years) were recruited between 1979 and
1983 (Phase 1) from the Caerphilly Prospective Study (CaPS) and
re-examined 20 years later at 65–83 years of age (Phase 5).
Participants included 750 and 898 subjects with either Phase 1
and/or Phase 5 data on exposure and outcomes. Outcome measures
were walking speed and balance time and exposures included
morning fasting serum cortisol (Phase 1) and four salivary samples
on 2 consecutive days (Phase 5).
Results Faster walking speed was associated with higher morning cortisol
at Phase 1 [coefficient per standard deviation (SD) increase 0.68,
95% confidence interval (95% CI) 0.09–1.27; P¼ 0.02] though this
was attenuated after adjustment for covariates (coefficient per SD
increase 0.45; 95% CI –0.16 to 1.07; P¼ 0.15). Higher night-time
cortisol at Phase 5 was associated with slower speed (coefficient per
SD increase –1.06; 95% CI –1.60 to –0.52; P< 0.001) and poorer
balance (odds ratio of top tertile vs bottom 2.49; 95% CI
1.63–3.81; P< 0.001). Worst performance was seen for men with
a poor morning response (Phase 1) and less nocturnal decline
(Phase 5).
Conclusions Dysregulation of the hypothalamic pituitary adrenal (HPA) axis is
associated with worse physical performance in later life. This may
reflect a causal effect of the HPA axis on ageing or that ageing itself
is associated with reduced HPA reactivity.
Keywords HPA axis, physical capability, healthy ageing
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Introduction
Evidence from animal1 and human2 studies suggest
that the hypothalamic pituitary adrenal (HPA) axis
contributes to biological ageing. The hypothalamus
controls both the circadian pattern and the absolute
levels of adrenocorticotropic hormone (ACTH) secre-
tion from the anterior pituitary, which in turn stimu-
lates the secretion of glucocorticoid hormones
(cortisol in man and corticosterone in rodents) from
the adrenal cortex.3 In some studies, aged animals
have been shown to have high glucocorticoid levels,
which also show a delayed return to normal following
a stressful event.1 This has been postulated to lead to
a positive feedback loop with reduced central inhib-
ition (‘glucocorticoid cascade’ hypothesis), and thus
even greater glucocorticoid responses over time.
Human data testing this hypothesis are limited,
though a recent report from the Whitehall II cohort
found that older individuals had a flatter diurnal
pattern.4
Sarcopenia is the loss of muscle mass that occurs
with ageing.5 This loss of muscle mass is associated
with a loss of physical performance such as the ability
to rise from a chair.6 One potential mechanism for
sarcopenia may be due to elevated life-course expos-
ure to cortisol6 a potent stimulus to protein catabol-
ism.7,8 For example, an excess of endogenous or
exogenous corticosteroids will result in steroid myop-
athy.8 It is unclear whether a similar state of sarco-
penia may result from normal physiological variations
of endogenous cortisol secretion. Only five studies
have reported associations between cortisol levels
and physical performance tests.4,9–13 Three of these
were based on small sample sizes of less than 60 par-
ticipants (therefore underpowered to detect clinically
or biologically important differences) and no study
had follow-up 44 years. One study found that
higher cortisol levels were associated with worse
physical performance but this was inconsistent;12
women with higher cortisol levels showed worse per-
formance on a balance test (tandem stand), whereas
men with higher levels had worse chair rises and
timed walk test. The same group also demonstrated
that higher cortisol was associated with a loss of grip
strength over a 4-year period for men and women
combined.11 In the Whitehall II study, participants
with higher daytime cortisol (compared with the nor-
mative group) had slower walk time tests.4 No study
has examined whether changes in cortisol secretion
are more strongly associated with physical perform-
ance. The Caerphilly Prospective Study (CaPS) has
two sets of cortisol measures over a 20-year period
in a large population sample of men from South
Wales. We hypothesized that either elevated cortisol
or lack of diurnal variability as a marker of HPA dys-
regulation would be associated with worse physical
performance and that subjects with an increase in
cortisol levels would perform worse than those
whose levels simply tracked over time.
Methods
Participants
The CaPS14 was set up to examine risk factors for
cardiovascular disease but as subjects became older
additional age-related phenotypes were added. The
baseline study (Phase 1) tried to contact all men
aged 45–59 years from Caerphilly and adjacent vil-
lages. A total of 2512 men (response rate of 89% of
those who were eligible) were seen between 1979 and
1983. These men have been followed up four more
times, the last being Phase 5 when the men were
65–83 years old. At Phase 2, an additional 447 men
were recruited who had been missed in Phase 1
(‘reconstructed cohort’).
Clinical and questionnaire-based data
At each phase, men completed a questionnaire and
had anthropometric measures taken at an evening
clinic. At Phase 2, the 30-item General Health
Questionnaire, a validated measure of minor psycho-
logical morbidity, was included.15 Socio-economic
status was derived using the subjects’ reported occu-
pation and the Registrar General’s classification
(I—professional, V—unskilled manual). Men were
classified into never, past or 1–14, 15–24 and
525 cigarettes per day (Phase 1), or never, past or
1–12 and 513 cigarettes per day (Phase 5) to produce
roughly equal-sized groups. Alcohol consumption
(units per week) was derived from a food frequency
questionnaire. At each phase, we identified subjects
on corticosteroid medications. At the clinic, height
was measured in metres using a stadiometer and
weight in kilograms using standardized scales.
Physical performance measures
These measures were first introduced in Phase 5. The
‘get up and go’ test16 is a standardized objective
measure of functional leg strength, power, mobility
and balance integrating several basic mobility man-
oeuvres. The participant is timed rising from a chair,
walking 3 m at their usual speed, turning, walking
back and sitting down. The test was performed
twice with the mean time taken for analysis. The ‘fla-
mingo’ test measures the ability to maintain postural
stability in the upright position17 and predicts falls in
older persons.18 Participants stood on their preferred
leg while lifting the other leg, keeping eyes open. The
position was held for as long as possible up to a
maximum of 30 s. The flamingo test was performed
twice, unless the maximum score of 30 s was achieved
in the first attempt. The best score was used in the
analysis.
Cortisol measures
For Phase 1, participants attended an early morning
clinic and had a fasting blood sample taken. Phase 1
samples for serum cortisol were frozen at –208C,
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assayed within 3 months of collection and measured
by radioimmunoassay.19 The overall coefficient of
variation for serum cortisol (n¼ 135 pairs) was
16%.14 At Phase 5, men were shown how to collect
saliva using plain cotton wool swabs (salivettes—
Sarstedt) at home. Subjects were instructed to
gently chew on the salivettes so that a saliva sample
of 0.5–1 ml was obtained within a minute. Subjects
were requested to take samples on waking, 30 min
later, and at 2 pm and 10 pm on 2 consecutive days.
Samples were stored in a domestic fridge until posted
back to the researchers with a datasheet to indicate
the actual times of sampling. Samples were frozen
at –408C and subsequently assayed by radio-
immunoassay20 in a laboratory specializing in
high-throughput cortisol assays (Dresden LabService
GmbH). The inter-assay coefficient of variation for
the salivary cortisols (118 plates) was 4% at both
low (5.3 nmol/l) and high (39.0 nmol/l) controls.
Statistical analysis
Cortisol has a marked circadian rhythm and therefore
the time of day at which cortisol is sampled affects
the cortisol level. At Phase 1, the time a man attended
the morning clinic varied by 6 hours. We therefore
adjusted the observed values for the time of sampling
by fitting a polynomial function to the association
between cortisol level and time of measurement
(‘fracpoly’ option in the Stata software)21 and
adding the residuals from the best fit model to the
overall mean cortisol value as has been previously re-
ported.14 The Phase 5 samples were taken at specific
time points (though individuals’ waking times vary)
with a much narrower range of times and we found
there was relatively little variability in sampling times.
In addition, actual time of sampling did not improve
the model fit or predict cortisol levels using either a
linear or indefinite article polynomial function for
time. Further analyses did not, therefore, adjust for
time of sampling. Participants were requested to write
any comments relating to problems with taking the
samples. In five cases, subjects reported that they did
not take the samples at the specified time points.
As well as the morning (mean of waking and 30 min
sample) and night-time values, we derived three add-
itional measures commonly used in epidemiological
studies.22 These were ‘Cortisol Awakening Response’
(CAR) (difference between the 30 min post waking
sample and the waking sample), diurnal drop (differ-
ence between morning and evening samples) and
area under the curve (AUC) for all measures. We
used the average of the measures across 2 days
unless they only returned measures for 1 day.
The distribution of the get up and go test is posi-
tively skewed, so we converted it into walking speed
(metres per minute), as detailed in a large recent
meta-analysis examining physical capability and mor-
tality.23 This normalized the data to a large degree.
We used the average of two attempts. Balance time
from the flamingo test was dichotomized at the
20th centile (around 3.75 s) as it was highly skewed
and those in this group were classified as ‘poor bal-
ance’ compared with the rest of the sample. This is
the same analytical approach as adopted in a recent
study examining socio-economic disadvantage from
childhood to adulthood and locomotor function in
old age.24
We used linear regression models to analyse walking
speed and logistic regression analysis for balance
time. Serum cortisol levels represent total protein
bound and free cortisol concentrations in the blood,
which are around 20 times higher than the free cor-
tisol concentrations found in saliva. We therefore con-
verted the absolute levels to phase-specific z-scores by
calculating the difference between the observed value
from the mean and dividing by the standard devi-
ation. We modelled cortisol both as a continuous vari-
able and in three equal groups (tertiles) to examine
for departures from linearity. As night-time cortisol
and the AUC for cortisol were positively skewed, we
transformed them (loge) before converting them to
z-scores. We chose potential confounders for the mul-
tivariable models from the previous literature and
examined associations with age,25 adiposity,25,26
socio-economic status,27 smoking status,28 alcohol
consumption29 and psychological morbidity.30 As we
failed to find any association between socio-economic
status, alcohol and psychological morbidity with cor-
tisol, our final multivariable model only adjusted for
age, body mass index (BMI) and smoking status mea-
sured at the same phase as the cortisol assay. To
examine for the long-term effects of different cortisol
patterns, we undertook post hoc analyses and dichot-
omized cortisol into the top tertile vs low and middle
groups at Phases 1 and 5 and created four subgroups
(low–medium Phases 1 and 5, low–medium Phase 1
and high Phase 5, high Phase 1 and low–medium
Phase 5, high Phases 1 and 5). We formally tested
for an interaction effect between Phases 1 and 5 cor-
tisol levels.
We undertook a series of further sensitivity analyses.
As we did not have the actual time of waking for
Phase 1 cortisol, it was possible that older subjects
had artefactually lower morning cortisol levels by
virtue of having woken earlier and, therefore, had a
greater diurnal drop by the time they had arrived at
clinic. We therefore examined whether the cortisol
performance association differed by whether they at-
tended clinic early or later on the basis that this bias
would be less marked in subjects attending clinic later
in the morning so that any difference in waking was
attenuated. We also used the time of waking reported
at Phase 5 as a proxy for Phase 1 and tested whether
adjustment made any difference.
Some subjects were unable to perform the tests be-
cause of surgery, injury, other health problems or un-
willingness and had missing data. We therefore
repeated the analyses by classifying these subjects as
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in the bottom 20% of the distribution. As there is no
standard way to analyse diurnal drop, we carried out
a sensitivity analysis using first waking cortisol and
then 30 min post waking cortisol as the anchor for the
diurnal drop. To maximize the precision of results, the
analysis of associations between Phase 5 cortisol and
physical performance included some men who did not
have cortisol measured at Phase 1. We have addition-
ally repeated analyses presented in Tables 2 and
3 including only men at Phase 5 who also had
Phase 1 cortisol measures.
Ethical approval
Ethical approval was given for the CaPS by the Ethics
Committee of the Division of Medicine of the former
South Glamorgan Area Health Authority. Approval for
Phase 5 came from the South East Wales Research
Ethics Committee and for the cortisol assays from
the North West Wales Research Ethics Committee.
Results
At Phase 1, 2143 men had a blood sample taken be-
tween 6 and 12 am (85% of eligible men). At Phase 5,
7837 salivary cortisol samples were collected from
1034 participants (response rate of 86.4% with mean
number of samples per man of 7.6). The median time
lag and inter-quartile range between Phases 1 and 5
were 21.8 (20.9–22.6) years. A total of 61 samples
from 30 subjects were censored as the saliva values
were thought to be artefactually high (4100 nmol/l).
This problem has been observed in other large-scale
epidemiological studies.22 A further 11 participants on
oral corticosteroid medication were excluded. Of
the remaining 962 men, 898 had walking speeds
and 911 had balance times. Of the participants at
Phase 1 with serum cortisol samples, 750 had walking
speeds and 756 had balance times. The number of
men who had cortisol measures at both Phases 1
and 5 was 735.
Table 1 shows the basic descriptive data for the ex-
posures, confounders and outcomes. Men at Phase 5
were 20 years older, had higher BMI and were far
more likely to be never or ex-smokers. The
time-adjusted serum cortisol at Phase 1 was
443.7 nmol/l, whereas the peak morning saliva level
at Phase 5 was 20.7 nmol/l (assuming a 20-fold con-
version factor this is equivalent to 414 nmol/l).
Whereas morning cortisol decreased with age for
men in Phase 1 (b per year age¼ –1.37; 95% CI
2.59 to –0.14; P¼ 0.03), it increased with age for
men in Phase 5 (b per year age¼ 0.25; 95% CI
0.08–0.42; P¼ 0.004). Current smoking was associated
with higher morning cortisol at both Phases 1 and 5
(P-value for linear trend < 0.001 and P¼ 0.02,
respectively).
Table 2 shows the relationship between cortisol
measures in Phases 1 and 5 with walking speed.
Higher morning cortisol in Phase 1 was associated
with a faster speed (P¼ 0.02) though this was atte-
nuated after adjustment for the other covariates
(P¼ 0.15). There was little evidence of an association
between morning salivary cortisol at Phase 5 and
speed. Night-time cortisol levels showed a strong in-
verse association so that higher levels were associated
with slower speed and hence worse performance. This
effect looked nonlinear as it was more marked in the
top third. Similarly, subjects with the largest diurnal
drop (reflecting higher morning and lower night-time
levels) had greater speed and hence better perform-
ance but here the association was most marked in the
middle tertile. There was no strong association be-
tween the CAR and walking speed though there was
weak evidence (P¼ 0.07) in the fully adjusted model
that the top third of CAR had faster velocity. There
was no association between the AUC and speed (data
not shown).
There was no association between the Phase 1
morning cortisol and balance time (Table 3). Higher
morning cortisol at Phase 5 was associated with worse
balance (P¼ 0.006), but after adjustment for con-
founding this association was markedly attenuated
(P¼ 0.17). As with speed, higher night-time cortisol
levels were associated with worse balance but again
this effect was driven by the association in the top
tertile. This association persisted, albeit slightly
weaker, in the fully adjusted model. Neither the diur-
nal drop nor CAR was associated with worse balance.
Whereas greater AUC was weakly associated with
worse balance (P¼ 0.05), this was attenuated after
adjustment (P¼ 0.18) (data not shown).
There were only weak associations between the cor-
tisol measures at Phases 1 and 5 (range between
0.04 and 0.12 Spearman’s rank correlations). When
we examined cortisol patterns over time, we found
that the slowest walk speed was seen in subjects
with low–medium levels of cortisol at Phase 1 and
high night-time levels at Phase 5 (–3.13; 95% CI
4.64 to –1.63; P< 0.001) as compared with those
with high levels at both phases (–1.36; 95% CI –3.42
to 0.70; P¼ 0.19) though these differences were
attenuated in the final model (–2.12 vs –1.76)
(Supplementary Table S1). The same patterns were
seen with worse balance (Supplementary Table S2);
a formal test for interaction, however, found the vari-
ations between groups to be consistent with chance
(P¼ 0.51 for walking speed and P¼ 0.39 for balance
in age-adjusted models).
Sensitivity analyses
There was no difference in the age of participants
whether they attended the clinic early or late at
Phase 1, a surrogate for whether they woke up early
or late (data not shown). There was little effect on the
associations between Phase 1 cortisol and either walk-
ing speed or balance time, stratified by whether they
attended the clinic early or late and tests for
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interactions found variations to be consistent with
chance (data not shown). Adjustment for waking
time at Phase 5 made little difference to the results
(data not shown). Including subjects who could not
complete the tests made little difference to the results.
We found little difference in the association between
diurnal drop and walk speed when using waking cor-
tisol (b¼ 0.37; 95% CI: –0.14 to 0.87; P¼ 0.15; age
adjusted) or 30 min post waking (b¼ 0.43; 95%
CI 0.07 to 0.93; P¼ 0.10; age adjusted) as the
anchor point for the diurnal drop. As before, there
was no evidence of an association between diurnal
drop and balance. When we repeated our analysis
including only men with cortisol measures at both
Phases 1 and 5, the associations with walk speed, if
anything, slightly increased for most of the exposures
except the morning cortisol measure [Phase 5 morn-
ing cortisol (b¼ 0.31; 95% CI –0.29 to 0.90; P¼ 0.32),
night-time cortisol (loge) (b¼ –1.08; 95% CI –1.69 to
0.48; P< 0.001], diurnal drop (b¼ 0.69; 95% CI
0.11–1.28; P¼ 0.02) and CAR (b¼ 0.23; 95% CI
0.36 to 0.83; P¼ 0.44). Similarly, it made little dif-
ference to the associations between Phase 5 cortisol
measures and balance (data not shown), although the
association between higher night-time cortisol (loge)
and poorer balance was now slightly weaker
(OR¼ 1.17; 95% CI 0.94–1.45; P¼ 0.16; age adjusted).
Discussion
The results of this study showed that higher cortisol
levels in middle-aged men were associated with faster
walking speed in later life, whereas higher night-time
cortisol and a smaller diurnal drop, measured in later
life, were associated with slower speed. In contrast,
we found no effect of mid-life cortisol levels on later
life balance time, but higher morning cortisol and
higher night-time cortisol, measured contemporan-
eously, were associated with worse balance. Across
the 20 years, the most adverse pattern associated for
both speed and balance was seen in men with low–
medium cortisol in mid-life and high night-time
levels in later life, though this may have occurred
by chance and we were not well powered to detect
modest interactions.
There is increasing evidence that the pattern of
tissue exposure to glucocorticoids is a very important
determinant of glucocorticoid signalling and gene ac-
tivation,31 although in the current study we were
unable to assess ultradian rhythmicity. We had pre-
dicted that either elevated cortisol or lack of diurnal
variability, as markers of HPA dysregulation, would
be associated with worse physical performance and
that subjects with increasing cortisol levels would per-
form worse than those whose levels simply tracked
over time. In fact, our best predictor was higher
Table 1 Summary of demographic characteristics for Phases 1 and 5 of the Caerphilly cohort study
Variable n (%) Phase 1, 1979–83 n (%) Phase 5, 2002–04
Age (years) 2486 52.68 (4.55) 1143 73.40 (4.17)
BMI (kg/m2) 2470 26.16 (3.63) 1130 27.88 (4.30)
Serum cortisol (nmol/l)a 2143 443.68 (132.26) – –
Salivary cortisol (nmol/l)b
On waking – – 982 18.74 (10.99)
30 min post waking – – 993 20.68 (12.16)
Afternoon (2 pm) – – 995 8.24 (7.55)
Evening (10 pm) – – 998 4.17 (7.46)
Get up and go (m/min) – – 1061 34.67c (8.08)
– – – 35.00d
Flamingo tests (s) – – 1070 16.71e (11.67)
– – – 15.66f
Smoking status
Never 392 (17.5) 322 (30.3)
Ex-smoker 722 (32.3) 592 (55.6)
Current smoker 1124 (50.2) 150 (14.1)
Results are presented as mean (SD), unless otherwise stated.
aSerum cortisol level is adjusted for the time of sampling.
bSalivary cortisol samples are mean of samples on consecutive days and are unadjusted for the time of sampling.
cMean and get up and go speed from two attempts.
dMedian get up and go speed from two attempts.
eHighest flamingo time from two attempts.
fMedian flamingo time.
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night-time cortisol, which in turn contributed to less
diurnal variability, and correlates in other studies
with increased psychosocial stress.32 Our findings
that higher mid-life morning cortisol was associated
with better performance, and that there was little evi-
dence of an association between morning salivary cor-
tisol and physical performance in elderly men was
counter to our a priori hypothesis; however, this
may reflect an over-simplistic interpretation of the
physiological significance of high cortisol levels as
we shall discuss further.
We believe that a less responsive HPA axis, rather
than absolute cortisol levels per se, is more important
in determining physical performance. In our study,
cortisol levels decreased with age for middle-aged
men but increased with age for elderly men. The
latter observation is consistent with a Swedish
study,25 where higher morning cortisol was found in
older men and in the Whitehall II study where par-
ticipants with higher daytime cortisol (compared with
the normative group) were older.4 Our mid-life corti-
sol samples were taken after an overnight fast and by
venepuncture, both physiological stressors. It is pos-
sible that individuals with more dynamic (greater di-
urnal drop and lower night-time measures), hence a
healthier HPA axis, produced a greater stress-related
response and hence ‘biologically’ younger men had
higher morning levels. We therefore believe that a
heightened stress-induced morning response in a
normal population may be indicative of a healthier
Table 2 Relationship between cortisol measures and get up and go speed in Phases 1 and 5
Unadjusted Age adjusted
Age, BMI and smoking
status adjusted
Get up and go (m/min) Get up and go (m/min) Get up and go (m/min)
b 95% CI P-value b 95% CI P-value b 95% CI P-value
Phase 1, n¼ 750
Cortisola 0.68 0.09 to 1.27 0.02 0.54 –0.03 to 1.11 0.07 0.45 –0.16 to 1.07 0.15
Tertile 1 – – – – – – – – –
Tertile 2 0.97 –0.41 to 2.34 0.17 1.01 –0.32 to 2.34 0.14 0.81 –0.57 to 2.19 0.25
Tertile 3 1.51 0.11 to 2.91 0.04 1.19 –0.16 to 2.54 0.09 1.10 –0.33 to 2.53 0.13
Phase 5, n¼ 898
Morning cortisolb –0.08 –0.61 to 0.45 0.76 0.11 –0.40 to 0.62 0.67 –0.12 –0.64 to 0.40 0.65
Tertile 1 – – – – – – – – –
Tertile 2 1.01 –0.25 to 2.27 0.12 1.27 0.06 to 2.49 0.04 0.89 –0.35 to 2.13 0.16
Tertile 3 0.04 –1.23 to 1.30 0.95 0.66 –0.56 to 1.89 0.29 0.28 –0.96 to 1.51 0.66
Night-time cortisolc –1.28 –1.80 to –0.76 <0.001 –0.96 –1.46 to –0.45 <0.001 –1.06 –1.60 to –0.52 <0.001
Tertile 1 – – – – – – – – –
Tertile 2 –0.87 –2.11 to 0.37 0.17 –0.21 –1.41 to 1.00 0.74 –0.37 –1.59 to 0.84 0.55
Tertile 3 –3.48 –4.71 to –2.24 <0.001 –2.76 –3.96 to –1.55 <0.001 –2.48 –3.73 to –1.22 <0.001
Diurnal dropd 0.33 –0.20 to 0.85 0.22 0.40 –0.11 to 0.91 0.12 0.33 –0.20 to 0.86 0.22
Tertile 1 – – – – – – – – –
Tertile 2 1.95 0.68 to 3.21 0.003 2.02 0.81 to 3.24 0.001 1.66 0.42 to 2.90 0.01
Tertile 3 1.08 –0.18 to 2.34 0.09 1.50 0.28 to 2.72 0.02 1.15 –0.09 to 2.38 0.07
CARe 0.20 –0.33 to 0.74 0.46 0.27 –0.25 to 0.78 0.31 0.34 –0.19 to 0.87 0.21
Tertile 1 – – – – – – – – –
Tertile 2 0.39 –0.87 to 1.66 0.54 0.44 –0.78 to 1.65 0.48 0.70 –0.52 to 1.93 0.26
Tertile 3 0.98 –0.29 to 2.25 0.13 1.02 –0.20 to 2.24 0.10 1.15 –0.08 to 2.39 0.07
n¼number of observations.
All cortisol measures have been z-scored.
aTime-adjusted serum cortisol.
bMorning salivary cortisol is the average of the mean waking and 30 min post wakening samples on consecutive days.
cMean night-time cortisol over 2 consecutive days.
dDiurnal drop is the difference between morning and night-time salivary cortisol over 2 consecutive days.
eCAR is the difference between the 30 min post waking sample and the waking sample over 2 consecutive days.
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HPA axis, though this interpretation may not be
shared by all. This is supported by the modest positive
correlation between Phase 1 morning cortisol and di-
urnal variation at Phase 5 so that men with higher
morning levels showed greater diurnal variation 20
years later. A similar argument to this has been
made in relation to the CAR, which is larger in
healthy individuals33 and may reflect an adaptive
‘boost’ response32 where the body anticipates having
to cope with stressful stimuli—the ability to mount
such a response being a marker of a healthier HPA
axis. Our data therefore suggest that individuals with
the least responsive HPA axis have worse performance
measures in later life, although we would have ex-
pected CAR to be more strongly associated with phys-
ical performance.
There are seven relevant publications from six inde-
pendent studies (Supplementary Table S3). Three of
these studies had less than 100 participants. The best-
powered studies came from the Longitudinal Aging
Study Amsterdam (LASA)11,12 and the Whitehall II
study.4 The LASA study found that subjects in the
top fourth (or above the top quartile) of morning
and evening cortisol levels had greater loss of grip
strength11 and that total cortisol was associated
with worse total performance score for women where-
as high evening cortisol was associated with worse
total performance for men and women.12 They had
no measure to derive the CAR and did not specifically
test for the diurnal drop. In the Whitehall II study,4
individuals with slower walk time were more likely to
show a smaller diurnal drop, consistent with our
Table 3 Relationship between cortisol measures and flamingo in Phases 1 and 5
Unadjusted Age adjusted
Age, BMI and smoking
status adjusted
Low flamingo (bottom 20%) Low flamingo (bottom 20%) Low flamingo (bottom 20%)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Phase 1, n¼ 756
Cortisola 1.00 (0.83–1.20) 0.98 1.06 (0.87–1.28) 0.58 1.06 (0.86–1.32) 0.58
Tertile 1 1 1 1
Tertile 2 1.13 (0.74–1.73) 0.58 1.14 (0.73–1.77) 0.56 1.10 (0.68–1.78) 0.71
Tertile 3 0.94 (0.60–1.46) 0.78 1.08 (0.68–1.71) 0.74 1.08 (0.65–1.81) 0.76
Phase 5, n¼ 911
Morning cortisolb 1.24 (1.06–1.44) 0.006 1.20 (1.03–1.41) 0.02 1.13 (0.95–1.35) 0.17
Tertile 1 1 1 1
Tertile 2 0.71 (0.46–1.10) 0.13 0.64 (0.41–1.01) 0.06 0.81 (0.50–1.31) 0.39
Tertile 3 1.33 (0.89–1.98) 0.17 1.15 (0.76–1.75) 0.50 1.12 (0.71–1.76) 0.64
Night-time cortisolc 1.33 (1.12–1.58) 0.001 1.23 (1.03–1.47) 0.02 1.27 (1.03–1.56) 0.02
Tertile 1 1 1 1
Tertile 2 1.23 (0.78–1.96) 0.37 1.01 (0.63–1.63) 0.96 1.13 (0.68–1.89) 0.63
Tertile 3 2.49 (1.63–3.81) <0.001 2.09 (1.35–3.24) 0.001 2.30 (1.41–3.74) 0.001
Diurnal sloped 1.17 (0.98–1.40) 0.07 1.18 (0.99–1.42) 0.06 1.08 (0.88–1.31) 0.47
Tertile 1 1 1 1
Tertile 2 0.83 (0.54–1.27) 0.39 0.82 (0.52–1.27) 0.37 0.88 (0.55–1.42) 0.61
Tertile 3 1.17 (0.78–1.76) 0.45 1.08 (0.71–1.65) 0.71 0.96 (0.60–1.51) 0.86
CARe 1.05 (0.88–1.26) 0.59 1.04 (0.87–1.25) 0.67 1.02 (0.84–1.25) 0.82
Tertile 1 1 1 1
Tertile 2 0.81 (0.52–1.26) 0.34 0.79 (0.50–1.25) 0.32 0.76 (0.47–1.24) 0.27
Tertile 3 1.26 (0.83–1.90) 0.28 1.29 (0.84–1.97) 0.24 1.24 (0.78–1.95) 0.36
All cortisol measures have been z-scored.
n¼number of observations
aTime-adjusted serum cortisol.
bMorning salivary cortisol is the average of the mean waking and 30 min post wakening samples on consecutive days.
cMean night-time cortisol over 2 consecutive days.
dDiurnal drop is the difference between morning and nighttime salivary cortisol over 2 consecutive days.
eCAR is the difference between the 30 min post waking sample and the waking sample over 2 consecutive days.
HPA AXIS AND PHYSICAL PERFORMANCE 1699
findings. This was based on a large sample of subjects
but was cross-sectional in nature. Our findings are
also consistent with the clinical concept of clinical
frailty. In a recent study of 214 older women,34 a
positive association was found between evening
measures of cortisol and increasing levels of frailty.
The main theories of ageing can be classified as evo-
lutionary, molecular, cellular and system based, and
there may be interaction at these levels.35 The neu-
roendocrine aspects of the system-based theory derive
from studies that show that exposure to high levels of
corticosteroids results in memory loss and hippocam-
pal shrinkage, which in animals is seen to be asso-
ciated with dendritic pruning. Since chronic stress
results in impaired glucocorticoid feedback and
enhanced levels of glucocorticoids, the glucocorticoid
cascade hypothesis suggests that the allostatic load
resulting from overactivity of the HPA axis weakens
the ability to adapt to changes in the environment
and is an important contributory cause of ageing in
the CNS. This hypothesis is consistent with our obser-
vations that higher night-time levels and to a lesser
degree smaller diurnal variability, were associated
with worse performance.
Other studies suggest that socio-economic status,27
psychosocial stressors32 and early life factors36 may be
important in determining the function of the HPA
axis. These factors may all contribute to life-course
influences on ageing and socio-economic differences
in physical performance.24
Strengths and limitations
This study is based on approximately 1000 men who
have been followed up for 20 years. Whereas we only
had a single serum measure of cortisol at baseline,
this was not a simple waking sample but reflected a
response to the stressful stimuli of fasting and
venepuncture. At Phase 5, we had four measures of
salivary cortisol over 2 consecutive days that allowed
us to derive several functional measures. We used
standardized tests of physical performance that are
known to predict future disability,37 hospital admis-
sion38 and mortality.23 The long time period between
the Phase 1 measures and the Phase 5 performance
tests makes it unlikely that any associations are due
to reverse causation. The consistency of the pattern
that a less robust circadian regulation of cortisol
was associated with worse performance across this
time period provides further evidence that this asso-
ciation may be causal. In our final models, we
adjusted for BMI as a potential confounder though
this may over-adjust (and hence underestimate) the
true associations as it has been postulated that adi-
posity may be secondary to increased cortisol expos-
ure and may be an intermediary between cortisol and
physical performance.39 Our findings may not be gen-
eralizable to women though the studies cited above
suggest similar effects for women. By definition, our
observations are based on the healthy survivors of the
cohort who were able to take part in Phase 5. We
have previously demonstrated that subjects with ele-
vated cortisol and reduced testosterone levels had a
higher risk of cardiovascular disease possibly
mediated through insulin resistance.14 Thus subjects
with the most dysfunctional HPA axis are
under-represented in the final sample and this select-
ive loss would attenuate the true associations.
Unfortunately, participants at Phase 1 were not
asked what time they woke up. Hence, it is possible
that the decrease in cortisol with age at Phase 1 might
be explained by older men waking up earlier. We have
tried to examine this hypothesis and though we have
only done this indirectly, we failed to find any evi-
dence to suggest that this is the explanation. Finally,
it is important to consider the degree of measurement
error in trying to characterize the HPA axis. A random
measure of cortisol is a poor measure of the HPA axis
and though several measures across the day are
better, they are still less than ideal. More dynamic
tests, such as psychosocial40 or physiological stres-
sors,41 may provide more valid measures but are
costly and difficult to include in large population-
based studies. Our observation that the Phase 5 meas-
ures were more predictive than the earlier Phase 1
measure may simply reflect the different sampling
procedures, better assays methods with a smaller co-
efficient of variation and that data were collected over
2 days at Phase 5, hence reducing random error rather
than the relative importance of more contemporan-
eous measures.
In conclusion, we have demonstrated that mainten-
ance of good circadian regulation of HPA activity is
associated with better physical performance in later
life. This is consistent with a generalized theory that
HPA axis dysfunction may be associated with reduced
life expectancy and a faster rate of ageing. However, it
is also possible that early dysregulation of the HPA
axis is also a manifestation of more rapid ageing.
Early life factors, socio-economic status and psycho-
logical stressors may all contribute to life-course
influences on ageing and socio-economic differences
in physical performance which may, in turn, be
partially mediated by the HPA axis. Further work
needs to confirm these findings across other data
sets and examine whether there are modifiable factors
that may ameliorate these effects so that future pri-
mary prevention strategies can be designed and
evaluated.
Supplementary Data
Supplementary Data are available at IJE online.
Funding
New Dynamics of Ageing (RES-353-25-0001)
HALCyon programme, from which M.G. was funded.
1700 INTERNATIONAL JOURNAL OF EPIDEMIOLOGY
The HALCyon programme, funded by the New
Dynamics of Ageing (RES-353-25-0001), funded the
Phase 5 cortisol assays. The CaPS study was estab-
lished by Prof. Peter Elwood and the former MRC
Epidemiology Unit (South Wales) and was funded
by the MRC (UK).
Acknowledgements
The authors would like to thank Prof. Clemens
Kirschbaum for help, advice and undertaking the
Phase 5 cortisol assays.
Conflict of interest: None declared.
KEY MESSAGES
 This is the first study examining the relationship between repeat cortisol measures (over 20 years)
and physical performance in later life.
 Dysregulation of the HPA axis is associated with worse physical performance in later life.
 Higher night-time cortisol and a smaller diurnal drop measured contemporaneously in later life were
associated with worse physical performance.
 A heightened stress-induced morning cortisol response in a normal population may be indicative of a
healthier HPA axis.
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